Acūtis Diagnostics
1-844-522-8847
service@acutis.com
acutis.com

# Acutis Reveal™
# Pathogen Detected
## Status - FINAL COPY

## Patient

| | |
|---|---|
| Name | Patient, Test |
| Birth | 1/1/2001 |
| Gender | Female |
| ID | 1111-00112233 |

## Matrix - Pharyngeal Swab

| | |
|---|---|
| Accession # | 1234567 |
| Sample ID | ORDER-123 |
| Collection Date | 1/25/2021 4:13 AM |
| Received Date | 1/26/2021 6:07 AM |
| Reported Date | 1/26/2021 8:12 PM |

## Provider

| | |
|---|---|
| Doctor | Doctor, Test |
| Organization | Test Clinic |

## Bacterial (PIT)

| Test Name | Outcome |
|---|---|
| ***Streptococcus Pyogenes*** | **Detected** |

## Notes:

According to the ACP and the CDC, recommend antibiotics for the treatment of Group A Strep.

**Test System Details**

All testing was performed at Acutis Diagnostics, under the supervision of Dr. Ted E. Schutzbank. This is an FDA-approved assay, based on RT-PCR technology, designed to detect specific nucleic acid targets extracted from pharyngeal swabs. All results from this test must be considered in conjunction with the clinical history, epidemiological data and other data available to the clinician evaluating the patient. The performance of this assay has not been evaluated for asymptomatic or immunocompromised patients, nor has it been evaluated for monitoring treatment of infection. Please note that this assay cannot rule out infections caused by other viral or bacterial pathogens not tested. Analyte targets (viral sequences) may persist in vivo, independent of virus viability, so detection of analyte target(s) does not imply that the corresponding virus(es) are infectious, or are the causative agents for clinical symptoms. Additional follow-up testing by culture is required if the ARIES Group A Strep Assay result is negative and clinical symptoms persist, or in the event of an outbreak of acute rheumatic fever (ARF).

Laboratory Director: Marjorie Bon Homme, PhD, DABCC

Acutis Diagnostics; CLIA ID # 33D2087537; 400 Karin Ln., Hicksville, NY 11801